This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Editor's note: Seeking Alpha is proud to welcome Robert Henry Whelan as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
AFRAF AIBEF AF RYAAY AFLYY LUV
VIENNA (Reuters) - British Airways parent IAG (ICAG.L) plans to expand its long-haul network from Vienna with new budget brand Level, Chief Executive Willie Walsh said on Tuesday.
British Airways parent IAG plans to expand its long-haul network from Vienna with new budget brand Level, Chief Executive Willie Walsh said on Tuesday.
VIENNA (Reuters) - Austrian leisure airline Laudamotion said on Monday it had always paid its bills for planes leased from Lufthansa (LHAG.DE) in full and on time, rejecting allegations made by the German rival.
Austrian leisure airline Laudamotion said on Monday it had always paid its bills for planes leased from Lufthansa in full and on time, rejecting allegations made by the German rival.
FRANKFURT (Reuters) - Lufthansa plans to end an agreement to lease planes to Laudamotion, saying the Austrian leisure carrier has failed to meet payments, leading to a dispute with rival, and Laudamotion backer, Ryanair (RYA.I).
(July 13): They were the planes that promised a new era of profitable flying for airlines. Instead, a series of engine glitches has left much of the aviation industry with a severe case of jet lag.
GEC GE GNE AIBEF
Croissance toujours soutenue du trafic dans les aéroports gérés par VINCI Airports : +7,4 % au 2ème trimestre 2018
DUBAI/ABU DHABI (July 3): Etihad Airways is reorganising into seven business divisions and group CEO Tony Douglas is taking over direct responsibility of the airline business, as the Abu Dhabi-based group strives to return to profit.
Lufthansa's budget carrier Eurowings expects the transfer of planes from collapsed rival Air Berlin planes into its fleet to be completed by the end of July, it said on Friday.
BERLIN (Reuters) - Lufthansa’s (LHAG.DE) budget carrier Eurowings expects the transfer of planes from collapsed rival Air Berlin (AB1.DE) planes into its fleet to be completed by the end of July, it said on Friday.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Recently news items have appeared that Abu Dhabi based Etihad Airways is looking to defer or scrap part of the wide body aircraft it has on order with Boeing (BA) and Airbus (OTCPK:EADSF/OTCPK:EADSY) as part of its renewed strategy. The airline saw its investment strategy failing miserably as Air Berlin and Alitalia went into administration. This has resulted in the airline recognizing significant one-off charges in its 2016 results while in its 2017 results the airline has continued struggling with the failed strategy and saw fuel prices increasing, likely in excess to any demand increase in oil-related travel that tends to fill the premium classes of airlines.
BOE AIBEF BA
BERLIN/OSLO: Lufthansa is in contact with Norwegian Air Shuttle, which is also the subject of bid interest from British Airways owner IAG, as the German airline looks to get involved in an expected wave of deals in the sector, its CEO told a newspaper.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET